Stockscreener 앱 받기
2.09
18.99%
-0.49
시간 외 거래:
2.27
0.18
+8.61%
전일 마감가:
$2.58
열려 있는:
$2.26
하루 거래량:
448.53K
Relative Volume:
2.21
시가총액:
$6.01M
수익:
$556.00K
순이익/손실:
$149.00K
주가수익비율:
-0.1201
EPS:
-17.4
순현금흐름:
$-16.90M
1주 성능:
-18.68%
1개월 성능:
-16.40%
6개월 성능:
-26.67%
1년 성능:
-0.95%
1일 변동 폭
$2.00
$2.53
1주일 범위
$1.71
$3.00
52주 변동 폭
$1.71
$5.25
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
명칭
Cyclerion Therapeutics Inc
전화
617-621-7722
주소
301 BINNEY STREET, CAMBRIDGE, MA
CYCN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CYCN | 2.09 | 6.01M | 556.00K | 149.00K | -16.90M | -17.40 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-20 | 개시 | Truist | Buy |
| 2021-09-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-03 | 개시 | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc 주식(CYCN)의 최신 뉴스
Cyclerion Therapeutics Inc (CYCN) Quarterly 10-Q Report - Quartzy
Cyclerion Therapeutics stock hits 52-week low at $1.75 By Investing.com - Investing.com South Africa
Cyclerion Therapeutics stock hits 52-week low at $1.75 - Investing.com India
Where Are They Now? Ironwood Pharmaceuticals - Life Science Leader Magazine
Vascular Dementia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Charsire Biotech Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP - Barchart
cyclerion therapeutics, inc. Earnings dates - RTTNews
Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 8.1% - Defense World
Analyzing Cyclerion Therapeutics (NASDAQ:CYCN) and Seelos Therapeutics (NASDAQ:SEEL) - Defense World
Cyclerion appoints Regina Graul as CEO and President - Investing.com
Cyclerion Therapeutics Promotes Regina Graul, Ph.D., to Chief Executive Officer - citybiz
Regina Graul, Ph.D., Promoted to Chief Executive Officer - StreetInsider.com
Short Interest in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Expands By 10.9% - Defense World
Cyclerion Therapeutics - BioSpace
Head-To-Head Analysis: Genelux (NASDAQ:GNLX) and Cyclerion Therapeutics (NASDAQ:CYCN) - Defense World
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday - Quantisnow
12 Health Care Stocks Moving In Thursday's Intraday SessionAethlon Medical (NASDAQ:AEMD), Biomea Fusion ... - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday SessionAutonomix Medical (NASDAQ:AMIX), Avinger ... - Benzinga
Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 10.2% - Defense World
Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates - Yahoo Movies UK
How Much Did Cyclerion Therapeutics'(NASDAQ:CYCN) Shareholders Earn From Share Price Movements Over The ... - Yahoo New Zealand News
12 Best Biotech Penny Stocks to Invest In - Insider Monkey
Cyclerion Appoints Regina Graul, Ph.D., as President - citybiz
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator - GlobeNewswire
Cyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With Losses - Yahoo Finance
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer - Marketscreener.com
Cyclerion in Talks on Buyout Proposal for Drug Assets; CEO Offers to Make Equity Investment - Marketscreener.com
Rapport Therapeutics Appoints Chief Operating Officer and Scientific Advisory Board Member - Business Wire
Tisento Therapeutics Raises $81M in Series A Funding - FinSMEs
Bio Startup Tisento Launches With $81M and a Brain-Penetrating Drug in the Clinic - MedCity News
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Cyclerion Announces Reverse Stock Split - Yahoo Finance
A struggling biotech wraps its main assets into a new drug company - BioPharma Dive
Cyclerion Announces Definitive Agreement for Zagociguat and CY3018 - GlobeNewswire
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement - GlobeNewswire
Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as Chief Scientific Officer - Business Wire
BioMarin, Cyclerion Slash Workforce in the Name of Strategic Focus - BioSpace
Nasdaq Edges Higher; AngioDynamics Shares Plummet | Markets Insider - Markets Insider
Is Cyclerion Therapeutics (NASDAQ:CYCN) In A Good Position To Invest In Growth? - Yahoo Finance
Form 8-K Cyclerion Therapeutics, For: Jun 10 - StreetInsider.com
Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results - Yahoo Finance
David Greenspan's Slate Path Capital is Buying Coinbase, Stitch Fix, and More - Insider Monkey
Meme Penny Stocks Are Here to Stay; 3 For Your Summer Watchlist - Penny Stocks
Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat - GlobeNewswire
Hedge Fund and Insider Trading News: Dan Kamensky, Tiger Global Management, Bridgewater Associates, Standard General, Archegos Capital Management, Cyclerion Therapeutics Inc (CYCN), Sayona Mining Ltd (DMNXF), and More - Insider Monkey
Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress - GlobeNewswire
Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors - citybiz
Cyclerion Therapeutics Announces Departure of Chief Medical Officer - GlobeNewswire
IXICO selected by Cyclerion for new Alzheimer's disease study - PR Newswire
Cyclerion Therapeutics (NASDAQ:CYCN) Stock Quotes, Forecast and News Summary - Benzinga
Cyclerion Therapeutics Inc (NASDAQ:CYCN) Publishes The Results Of Its IW-6463 Phase 1 Transitional Pharmacology Study - BP Journal
Cyclerion Suspends Development of Olinciguat for Sickle Cell Disease - Sickle Cell Disease News
Cyclerion Therapeutics Inc (CYCN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):